Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

Esomeprazole for Prevention of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs

ClinicalTrials.gov ID: NCT00241553

Public ClinicalTrials.gov record NCT00241553. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 6:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Efficacy of Esomeprazole 40 mg Once Daily Versus Placebo or Esomeprazole 20 mg Once Daily Versus Placebo in Prevention of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs Including COX-2 Selective NSAIDs

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study was a multicentre, double-blind, randomised, placebo-controlled parallel group study consisting of 4 visits over a period of 6 months. The primary variable was to assess theefficacy of esomeprazole 40 mg orally qd (E40) or esomeprazole 20 mg orally qd (E20) versus placebo orally qd after 6 months of treatment for the prevention of relapse of upper GI symptoms associated with NSAID use, including COX-2 selective NSAIDs, in patients receiving daily NSAID therapy.

Study identification

NCT ID
NCT00241553
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
AstraZeneca
Industry
Enrollment
276 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 2001 (Type not available)
Primary completion
Feb 2003 (Actual)
Completion
Feb 2003 (Actual)
Last update posted
Jan 24, 2011

2001 – 2003

United States locations

U.S. sites
31
U.S. states
17
U.S. cities
31
Facility City State ZIP Site status
Research Site Tallassee Alabama — —
Research Site Phoenix Arizona — —
Research Site Garden Grove California — —
Research Site Orange California — —
Research Site Bradenton Florida — —
Research Site Coral Gables Florida — —
Research Site Hollywood Florida — —
Research Site St. Petersburg Florida — —
Research Site Tavares Florida — —
Research Site Zephyrhills Florida — —
Research Site Nampa Idaho — —
Research Site Elkhart Indiana — —
Research Site Evansville Indiana — —
Research Site Newburgh Indiana — —
Research Site Wichita Kansas — —
Research Site Hollywood Maryland — —
Research Site Butte Montana — —
Research Site Princeton New Jersey — —
Research Site Toms River New Jersey — —
Research Site Endwell New York — —
Research Site Hewlett New York — —
Research Site Charlotte North Carolina — —
Research Site Winston-Salem North Carolina — —
Research Site Duncansville Pennsylvania — —
Research Site Erie Pennsylvania — —
Research Site Jackson Tennessee — —
Research Site Waco Texas — —
Research Site Edmonds Washington — —
Research Site Olympia Washington — —
Research Site Greenfield Wisconsin — —
Research Site Milwaukee Wisconsin — —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 105 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00241553, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 24, 2011 · Synced Oct 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00241553 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →